Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 The Changing Landscape of Neonatal Herpes Simplex Virus Disease.Journal of the Pediatric Infectious Diseases Society2021
2021 Variation in Diagnostic Testing and Empiric Acyclovir Use for HSV Infection in Febrile Infants.Hospital pediatrics.  11:922-930. 2021
2021 Clinical outcome and the role of antivirals in congenital cytomegalovirus infectionAntiviral Research.  191. 2021
2021 Neonatal Herpes Simplex Virus Disease: Updates and Continued ChallengesClinics in Perinatology.  48:263-274. 2021
2021 COVID-19 Vaccination of Adolescents and Young Adults of Color: Viewing Acceptance and Uptake With a Health Equity LensJournal of Adolescent Health.  68:844-846. 2021
2021 Initial guidance on use of monoclonal antibody therapy for treatment of coronavirus disease 2019 in children and adolescentsJournal of the Pediatric Infectious Diseases Society.  10:629-634. 2021
2021 Policy Statement: Antibiotic stewardship in pediatricsJournal of the Pediatric Infectious Diseases Society.  10:641-649. 2021
2021 Balancing Risks in the Time of COVID-19JAMA Pediatrics.  175:129-130. 2021
2021 Breast Milk and COVID-19: What Do We Know?Clinical Infectious Diseases.  72:131-132. 2021
2021 Multicenter Interim Guidance on Use of Antivirals for Children with Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2Journal of the Pediatric Infectious Diseases Society.  10:34-48. 2021
2020 Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2Journal of the Pediatric Infectious Diseases Society.  9:701-715. 2020
2020 Update From the Advisory Committee on Immunization PracticesJournal of the Pediatric Infectious Diseases Society.  9:645-649. 2020
2020 Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy cliniciansContemporary Clinical Trials Communications.  19. 2020
2020 Can SARS-CoV-2 Infection Be Acquired in Utero?: More Definitive Evidence Is Needed 2020
2020 Advances in the development of therapeutics for cytomegalovirus infectionsJournal of Infectious Diseases.  221:32-44. 2020
2019 Update from the Advisory Committee on Immunization PracticesJournal of the Pediatric Infectious Diseases Society.  8:495-500. 2019
2019 Update from the Advisory Committee on Immunization PracticesJournal of the Pediatric Infectious Diseases Society.  9:3-5. 2019
2019 Blood Viral Load in Symptomatic Congenital Cytomegalovirus InfectionJournal of Infectious Diseases.  219:1398-1406. 2019
2019 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  8:379-383. 2019
2018 Update From the Advisory Committee on Immunization PracticesJournal of the Pediatric Infectious Diseases Society.  7:270-274. 2018
2018 The tail wagging the dog (or the challenges faced when the financing of medicine gets ahead of the science of medicine)Journal of Clinical Microbiology.  56. 2018
2018 Antiviral approaches for the treatment of herpes simplex virus infections in Newborn InfantsAnnual Review of Virology.  5:407-425. 2018
2018 Update From the Advisory Committee on Immunization PracticesJournal of the Pediatric Infectious Diseases Society.  7:181-187. 2018
2018 Closer to Universal Newborn Screening for Congenital Cytomegalovirus Infection but Far Away from Antiviral Therapy in All Infected InfantsJournal of Pediatrics.  199:7-9. 2018
2018 Antiviral treatment of childhood influenza: An updateCurrent Opinion in Pediatrics.  30:438-447. 2018
2018 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  7:93-99. 2018
2018 Clinical markers and outcomes of neonates with herpes simplex virus deoxyribonucleic acid persistence in cerebrospinal fluid in disseminated and central nervous system infectionJournal of the Pediatric Infectious Diseases Society.  7:E30-E33. 2018
2017 Delayed recurrence of herpes simplex virus infection in the central nervous system after neonatal infection and completion of six months of suppressive therapyJournal of the Pediatric Infectious Diseases Society.  6:e177-e179. 2017
2017 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  6:311-316. 2017
2017 Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapyLancet Infectious Diseases.  17:e177-e188. 2017
2017 Preventing human papillomavirus–related cancers: we are all in this togetherAmerican Journal of Obstetrics and Gynecology.  216:576.e1-576.e5. 2017
2017 Update from the Advisory Committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  6:111-115. 2017
2017 Pathogenesis of Non-Zika Congenital Viral InfectionsJournal of Infectious Diseases.  216:S912-S918. 2017
2016 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  5:349-355. 2016
2016 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  5:101-104. 2016
2016 Advances in the prevention and treatment of congenital cytomegalovirus infectionCurrent Opinion in Pediatrics.  28:81-85. 2016
2015 Sequelae following postnatally acquired cytomegalovirus infection in very low-birth-weight neonates back to the futureJAMA Pediatrics.  169. 2015
2015 A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsisJournal of the Pediatric Infectious Diseases Society.  5:53-62. 2015
2015 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  5:3-6. 2015
2015 Acyclovir dosing and acute kidney injury: Deviations and directionJournal of Pediatrics.  166:1341-1344. 2015
2015 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  4:94-95. 2015
2015 Neonatal herpes simplex virus infection: Epidemiology and treatmentClinics in Perinatology.  42:47-59. 2015
2015 Neonatal Herpes Simplex Virus InfectionInfectious Disease Clinics of North America.  29:391-400. 2015
2015 Quantitative herpes simplex virus concentrations in neonatal infectionJournal of Pediatrics.  166:793-795. 2015
2014 Preventing herpes simplex virus in the newbornClinics in Perinatology.  41:945-955. 2014
2014 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  3:282-285. 2014
2014 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  3:94-97. 2014
2014 The scarlet HJournal of Infectious Diseases.  209:315-317. 2014
2014 Management of neonatal herpes simplex virus infection and exposure 2014
2014 Mother-to-child transmission of herpes simplex virusJournal of the Pediatric Infectious Diseases Society.  3. 2014
2014 The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approachClinical Pharmacology and Therapeutics.  96:380-389. 2014
2014 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  3:1-3. 2014
2013 Executive summary: Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: Recommendations from the national institutes of health, the centers for disease control and prevention, the HIV medicine association of the infectious diseases society of America, the pediatric infectious diseases society, and the American academy of pediatricsJournal of the Pediatric Infectious Diseases Society.  2:293-308. 2013
2013 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  2:309-311. 2013
2013 Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaJournal of Infectious Diseases.  207:709-720. 2013
2013 Maternal and neonatal herpes simplex virus infections 2013
2013 Acyclovir dosing in the neonatal period and beyondJournal of the Pediatric Infectious Diseases Society.  2:179-182. 2013
2013 Update from the advisory committee on immunization practicesJournal of the Pediatric Infectious Diseases Society.  2:97-99. 2013
2012 Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: A multicenter case seriesJournal of Pediatrics.  161. 2012
2011 Control of varicella disease, version 2.0Journal of Infectious Diseases.  203:297-298. 2011
2010 Determination of appropriate dosing of influenza drugs in pediatric patientsClinical Pharmacology and Therapeutics.  88:704-707. 2010
2010 Oseltamivir dosing for influenza infection in premature neonatesJournal of Infectious Diseases.  202:563-566. 2010
2010 Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of ageClinical Infectious Diseases.  50:221-228. 2010
2010 Targeted antiviral prophylaxis with oseltamivir in a summer camp settingJAMA Pediatrics.  164:323-327. 2010
2009 Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous systemJournal of Clinical Virology.  46. 2009
2009 Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infectionAntiviral Research.  83:207-213. 2009
2009 Treatment of congenital cytomegalovirus infection: Implications for future therapeutic strategiesJournal of Antimicrobial Chemotherapy.  63:862-867. 2009
2008 When Should You Initiate Acyclovir Therapy in a Neonate?Journal of Pediatrics.  153:155-156. 2008
2008 Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus diseaseJournal of Infectious Diseases.  197:836-845. 2008
2007 Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulationClinical Pharmacology and Therapeutics.  81:867-872. 2007
2007 Management of HSV encephalitis in adults and neonates: Diagnosis, prognosis and treatment 2007
2007 ReplyAmerican Journal of Obstetrics and Gynecology.  196. 2007
2006 Valacyclovir therapy to reduce recurrent genital herpes in pregnant womenAmerican Journal of Obstetrics and Gynecology.  194:774-781. 2006
2005 Diagnosis of herpes simplex virus infections of the CNS 2005
2005 Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous systemJournal of Infectious Diseases.  191:227-233. 2005
2004 Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosisAntiviral Research.  63:141-151. 2004
2004 Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutantsJournal of Infectious Diseases.  190:975-978. 2004
2004 Neonatal HSV infections: The global picture 2004
2004 Neonatal Herpes Simplex InfectionClinical Microbiology Reviews.  17:1-13. 2004
2003 Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trialJournal of Pediatrics.  143:16-25. 2003
2003 Molecular diagnosis of viral infections of the central nervous systemClinics in Laboratory Medicine.  23:843-865. 2003
2002 Herpes simplex virus infections in the neonatal periodInfections in Medicine.  19:462-474. 2002
2002 Pharmacotherapy of recurrent respiratory papillomatosisExpert Opinion on Pharmacotherapy.  3:1091-1099. 2002
2002 Meningitis in the Neonate.Current Treatment Options in Neurology.  4:239-248. 2002
2002 Antiretroviral pharmacokinetics in the paediatric population: A reviewClinical Pharmacokinetics.  41:1115-1133. 2002
2000 Juvenile onset recurrent respiratory papillomatosis: Possibilities for successful antiviral therapyAntiviral Research.  45:83-93. 2000
1999 Indicated versus spontaneous preterm delivery: An evaluation of neonatal morbidity among infants weighing ≤1000 grams at birthAmerican Journal of Obstetrics and Gynecology.  180:683-689. 1999
1999 Neuroinvasion of human herpesviruses 6 and 7 1999
1998 PCR: A new diagnostic tool that re-defines spectrum of HSV disease 1998
1998 Fetal heart rate characteristics at 25 to 28 weeks' gestation 1998
1998 Herpes simplex virusesClinical Infectious Diseases.  26:541-555. 1998
1998 Human herpesvirus-6: Neurologic implications of a newly-described viral pathogenJournal of NeuroVirology.  4:474-485. 1998
1998 Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancyAmerican Journal of Obstetrics and Gynecology.  179:846-851. 1998
1998 Prevention and treatment of congenitally and perinatally acquired herpesvirus infectionsInternational Antiviral News.  6:78-82. 1998
1998 The effect of maternal magnesium sulfate treatment on neonatal morbidity in ≤ 1000-gram infants 1998
1997 Treatment of viral infections during pregnancy and the neonatal periodClinics in Perinatology.  24:267-283. 1997
1996 Antiviral resistance: Mechanisms, clinical significance, and future implicationsJournal of Antimicrobial Chemotherapy.  37:403-421. 1996
1996 Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus diseaseJournal of Infectious Diseases.  174:1162-1167. 1996
1995 Protein synthesis-dependent induction of interleukin-1β by lipopolysaccharide is inhibited by dexamethasone via mRNA destabilization in human astroglial cellsJournal of Clinical Immunology.  15:199-204. 1995
1995 Antiviral resistance - an emerging problemAntiviral Research.  26:365-368. 1995
1995 Antiviral resistance in clinical practiceAntiviral Research.  26:423-438. 1995
1995 Assays for antiviral drug resistanceAntiviral Research.  26:403-413. 1995
1995 Models of antiviral resistanceAntiviral Research.  26:415-422. 1995
1995 Modulation of expression of genes involved in the inflammatory response by lipopolysaccharide and temperature in cultured human astroglial cells 1995
1995 Molecular mechanisms of antiviral resistanceAntiviral Research.  26:369-401. 1995
1995 Research initiatives in studies of antiviral resistance and consensus points and recommendationsAntiviral Research.  26:439-452. 1995

Chapter

Year Title Altmetric
2018 Neonatal herpes simplex virus infection.  119-126. 2018
2018 Antiviral Agents.  1551-1567.e6. 2018
2018 Herpes Simplex Virus.  1056-1065.e3. 2018
2018 Introduction to Herpesviridae.  1055-1055.e1. 2018
2017 Neurologic sequelae of congenital and perinatal infections.  501-522. 2017
2017 Neonatal herpes simplex virus infection.  395-410. 2017
2016 Antiviral therapy.  210-225. 2016
2016 Rubella virus.  1381-1393. 2016
2014 Vaccines for viral diseases with significant central nervous system manifestations 2014
2012 Neonatal herpes simplex virus and congenital cytomegalovirus infections.  203-217. 2012
2012 Antiviral Agents.  1502-1518.e10. 2012
2010 Herpes simplex viruses 1 and 2.  1275-1280. 2010
2007 Antiviral therapy of HSV-1 and-2.  1153-1174. 2007
2007 HSV-1 and 2: Pathogenesis and disease.  589-601. 2007
2007 Immunotherapy of HSV infections-Antibody delivery.  1332-1338. 2007
2005 Neonatal herpes simplex virus infection.  395-410. 2005

Principal Investigator On

  • (SCOUT CAP) A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER
  • A Phase II, Single-Stage, Single Arm Investigation of Oral Valganciclovir Therapy in Infants with Asymptomatic Congenital Cytomegalovirus Infection  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Burden of Neonatal Herpes Simplex Virus Infections: Disease Incidence, Adequacy of Diagnostic Assessment, Disease Outcome, and Societal Costs  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (RDCRC)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Cross-sectional Cohort Study to Determine the Prevalence of Soil Transmitted Helminth (STH) Infections in School Age Children in a Rural Poor Community in Southern Alabama  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • Efficacy of Antiviral Suppression Therapy after Neonatal HSV Infection of CNS R34 Planning  awarded by Duke University
  • Monitoring Juvenile Onset Recurrent Respiratory Papillomatosis  awarded by EASTERN VIRGINIA MEDICAL SCHOOL
  • Monitoring Juvenile Onset Recurrent Respiratory Papillomatosis  awarded by EASTERN VIRGINIA MEDICAL SCHOOL
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by CUBIST PHARMACEUTICALS
  • Private Grant  awarded by CELLEX, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ANTIVIRUS THERAPEUTICS, INC.
  • Private Grant  awarded by ALIOS BIOPHARMA
  • Private Grant  awarded by AICURIS ANTI-INFECTIVE CURES GMBH
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by SPEEDX PTY. LTD.
  • Retrospective Assessment of Juvenile Onset Recurrent Respiratory Papillomatosis  awarded by EASTERN VIRGINIA MEDICAL SCHOOL
  • Investigator On

  • Cross Sectional Cohort Study to Determine the Prevalence of Soil Transmitted Helminth (STH) in School Age Children in Rural Alabama  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • Cross-sectional Cohort Study to Determine the Prevalence of Soil Transmitted Helminth Infections and Risk Factors for their Acquisition in Children in Southern Alabama  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • Emerging Antiviral Resistance in Congenital Cytomegalovirus Infection  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Pharmacometric Approaches to Precision Optimization of Ivacaftor Response in Cystic Fibrosis Patients  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Private Grant  awarded by GENMARK DIAGNOSTICS
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by NOVAVAX, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by MODERNATX INC
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by MODERNATX INC
  • Targeted Clinical Research to Address Select Viral Infections-A Phase II Randomized Six Weeks of Oral Valganciclovir Therapy in CMV Infants with Hearing Loss  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Targeted Clinical Research to Address Select Viral Infections-An Adaptive Pharmacokinetic, Pharmacodynamic, Concentration Response Investigation of CMX-001 in the Infants with Neonatal Herpes (HSV) Followed by Randomized Assessment  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Targeted Clinical Research to Address Select Viral Infections-An Adaptive, Sequential Study Evaluation Prevention of Neonatal Herpes Simplex Virus Disease: Detection of Maternal Herpes Simplex Virus Shedding at Delivery  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER
  • Teaching Activities

  • 52-401R - RESEARCH IN PEDIATRICS (Fall Term 2007)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2016)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2016)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2016)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2016)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2020)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2021)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2021)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2021)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2021)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Fall Term 2021)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2017)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2018)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2019)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2020)
  • 52-420 - PEDIATRIC INFECTIOUS DISEASE (Spring Term 2020)
  • STP299FL - INTRODUCTION TO PEDIATRIC INFECTIOUS DISEASE (Fall Term 2019)
  • Full Name

  • David Kimberlin